A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524843-11-00

Enrollment

Registered

2026-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Brief summary

Number of participants with adverse events (AE) and serious adverse events (SAE), Objective response rate (ORR)

Detailed description

Best Overall Response(BOR), Change in Target Lesion Tumor Size, Progression free survival (PFS), Disease Control Rate(DCR) at 12 Weeks, Duration Of Response (DoR), Overall Survival(OS), Serum concentration, Maximum plasma drug concentration (Cmax), Immunogenicity of study interventions in participants receiving treatment

Interventions

DRUGMYCOPHENOLATE MOFETIL

DRUGRilvegostomig

DRUGRAMUCIRUMAB

DRUGINFLIXIMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse events (AE) and serious adverse events (SAE), Objective response rate (ORR)	—

Secondary

Measure	Time frame
Best Overall Response(BOR), Change in Target Lesion Tumor Size, Progression free survival (PFS), Disease Control Rate(DCR) at 12 Weeks, Duration Of Response (DoR), Overall Survival(OS), Serum concentration, Maximum plasma drug concentration (Cmax), Immunogenicity of study interventions in participants receiving treatment	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 8, 2026